RxDoctor Payments Data

Jeremy Ruskin, MD

Clinical Cardiac Electrophysiology · Boston, MANPI 1952392524

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $102,339 of the $103,333 with a category attached, or 99.0%. It is spread thinly across 9 manufacturers, the largest accounting for just 23.3%. Reporting peaked in 2019 at $29,274 and has fallen 77.5% since, to $6,593 in 2025.

$103,333in general payments, 2019–2025

Across 33 payments — averaging $3131.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertex$24K
  • Sanofi-aventis U.S. LLC$20K
  • Jazz Pharmaceuticals Inc.$16K
  • Daiichi Sankyo Inc.$13K
  • Mallinckrodt Hospital Products Inc.$11K
  • Agios Pharmaceuticals, Inc.$10K
  • plus $9K from 3 others
$22,647in research payments, 2019–2025

Across 19 payments — averaging $1191.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Scientific Affairs, LLC$19K
  • Sanofi$3K

What the payments were for

  • Consulting fees$102,33999%
  • Travel & lodging$8641%
  • Food & beverage$1300%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$103,333 in reported general payments places this provider in the 80th percentile of 106 clinical cardiac electrophysiology providers in Massachusetts.

See all clinical cardiac electrophysiology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$19,100
Medicare patients
73
Services billed
169

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban67$99,340
MultaqDronedarone Hcl18$31,326
XareltoRivaroxaban16$13,045
Metoprolol Succinate69$1,513
Flecainide Acetate16$1,202
Mexiletine Hcl18$834
Digoxin18$666
Atorvastatin Calcium29$491

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$4,980$99,34067 claims
Sanofi-aventis U.S. LLCMultaq$20,137$31,32618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 106 clinical cardiac electrophysiology providers in Massachusetts.

Other clinical cardiac electrophysiology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →